FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224016822> ?p ?o ?g. }

• W4224016822 endingPage "788" @default.
• W4224016822 startingPage "782" @default.
• W4224016822 abstract "Tarloxotinib, a hypoxia-activated prodrug of an irreversible pan-ErbB tyrosine kinase inhibitor, represents a novel therapeutic which exploits the tumor-specific hypoxic environment as a mechanism for tumor-specific targeting. This study evaluated the safety and activity of tarloxotinib in recurrent or metastatic (R/M) cutaneous (CSCC) or head and neck squamous cell carcinoma (HNSCC). This was a phase II two-stage multi-centre study for patients with R/M HNSCC or CSCC. All patients received tarloxotinib 150 mg/m2 on days 1,8,15 and 22 in a 28-day cycle. Stage 1 enrolled patients in three cohorts: p16-negative HNSCC, p16-positive oropharyngeal SCC, and CSCC. In order for a cohort to proceed to stage 2 a minimum response rate of 5% was required. 30 patients were enrolled: 23% were female with median age of 63.3 years. The median duration of follow-up was 20 weeks. The median progression-free survival was 2.0 months (95%CI 1.8–3.4) and median overall survival 5.7 months (95%CI 3.6-8.0). Treatment was well tolerated. The objective response rate was 3% with one patient with CSCC having a partial response. Hypoxia-activated prodrugs represent a novel approach to cancer treatment, however, no clinically meaningful benefit for tarloxotinib in R/M HNSCC or CSCC was identified in this study. NCT02449681 (May 20, 2015)." @default.
• W4224016822 created "2022-04-19" @default.
• W4224016822 creator A5027993575 @default.
• W4224016822 creator A5031092629 @default.
• W4224016822 creator A5032225151 @default.
• W4224016822 creator A5034906272 @default.
• W4224016822 creator A5039581724 @default.
• W4224016822 creator A5043871151 @default.
• W4224016822 creator A5060469120 @default.
• W4224016822 creator A5069613777 @default.
• W4224016822 date "2022-04-18" @default.
• W4224016822 modified "2023-09-27" @default.
• W4224016822 title "A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin" @default.
• W4224016822 cites W152279435 @default.
• W4224016822 cites W2019607817 @default.
• W4224016822 cites W2024003704 @default.
• W4224016822 cites W2093207065 @default.
• W4224016822 cites W2095640080 @default.
• W4224016822 cites W2096315055 @default.
• W4224016822 cites W2101157733 @default.
• W4224016822 cites W2102639464 @default.
• W4224016822 cites W2103134643 @default.
• W4224016822 cites W2109609800 @default.
• W4224016822 cites W2112845420 @default.
• W4224016822 cites W2113672655 @default.
• W4224016822 cites W2117985979 @default.
• W4224016822 cites W2133876772 @default.
• W4224016822 cites W2136800292 @default.
• W4224016822 cites W2136871952 @default.
• W4224016822 cites W2149412903 @default.
• W4224016822 cites W2149447281 @default.
• W4224016822 cites W2155752258 @default.
• W4224016822 cites W2160286086 @default.
• W4224016822 cites W2512509856 @default.
• W4224016822 cites W2602625620 @default.
• W4224016822 cites W2611630089 @default.
• W4224016822 cites W2759377993 @default.
• W4224016822 cites W2805968856 @default.
• W4224016822 cites W2891215954 @default.
• W4224016822 cites W2986633517 @default.
• W4224016822 cites W3088586143 @default.
• W4224016822 cites W3115703756 @default.
• W4224016822 doi "https://doi.org/10.1007/s10637-022-01230-w" @default.
• W4224016822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35435625" @default.
• W4224016822 hasPublicationYear "2022" @default.
• W4224016822 type Work @default.
• W4224016822 citedByCount "4" @default.
• W4224016822 countsByYear W42240168222022 @default.
• W4224016822 countsByYear W42240168222023 @default.
• W4224016822 crossrefType "journal-article" @default.
• W4224016822 hasAuthorship W4224016822A5027993575 @default.
• W4224016822 hasAuthorship W4224016822A5031092629 @default.
• W4224016822 hasAuthorship W4224016822A5032225151 @default.
• W4224016822 hasAuthorship W4224016822A5034906272 @default.
• W4224016822 hasAuthorship W4224016822A5039581724 @default.
• W4224016822 hasAuthorship W4224016822A5043871151 @default.
• W4224016822 hasAuthorship W4224016822A5060469120 @default.
• W4224016822 hasAuthorship W4224016822A5069613777 @default.
• W4224016822 hasBestOaLocation W42240168221 @default.
• W4224016822 hasConcept C108215921 @default.
• W4224016822 hasConcept C121608353 @default.
• W4224016822 hasConcept C126322002 @default.
• W4224016822 hasConcept C143998085 @default.
• W4224016822 hasConcept C178790620 @default.
• W4224016822 hasConcept C185592680 @default.
• W4224016822 hasConcept C2776530083 @default.
• W4224016822 hasConcept C2776833033 @default.
• W4224016822 hasConcept C540031477 @default.
• W4224016822 hasConcept C71924100 @default.
• W4224016822 hasConcept C7836513 @default.
• W4224016822 hasConcept C90924648 @default.
• W4224016822 hasConcept C98274493 @default.
• W4224016822 hasConceptScore W4224016822C108215921 @default.
• W4224016822 hasConceptScore W4224016822C121608353 @default.
• W4224016822 hasConceptScore W4224016822C126322002 @default.
• W4224016822 hasConceptScore W4224016822C143998085 @default.
• W4224016822 hasConceptScore W4224016822C178790620 @default.
• W4224016822 hasConceptScore W4224016822C185592680 @default.
• W4224016822 hasConceptScore W4224016822C2776530083 @default.
• W4224016822 hasConceptScore W4224016822C2776833033 @default.
• W4224016822 hasConceptScore W4224016822C540031477 @default.
• W4224016822 hasConceptScore W4224016822C71924100 @default.
• W4224016822 hasConceptScore W4224016822C7836513 @default.
• W4224016822 hasConceptScore W4224016822C90924648 @default.
• W4224016822 hasConceptScore W4224016822C98274493 @default.
• W4224016822 hasIssue "4" @default.
• W4224016822 hasLocation W42240168221 @default.
• W4224016822 hasLocation W42240168222 @default.
• W4224016822 hasOpenAccess W4224016822 @default.
• W4224016822 hasPrimaryLocation W42240168221 @default.
• W4224016822 hasRelatedWork W1996158748 @default.
• W4224016822 hasRelatedWork W2069688734 @default.
• W4224016822 hasRelatedWork W2159954396 @default.
• W4224016822 hasRelatedWork W2169631870 @default.
• W4224016822 hasRelatedWork W2185070997 @default.
• W4224016822 hasRelatedWork W2974748062 @default.
• W4224016822 hasRelatedWork W3003710118 @default.
• W4224016822 hasRelatedWork W3012537123 @default.

• next